National Heart, Lung, and Blood Institute; Submission for OMB Review; Comment Request, National Donor Research and Education Study-II

Federal RegisterDec 29, 1997

Ask Donna

What actually matters in this document.

Text

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Submission for OMB

Review; Comment Request, National Donor Research and Education Study-II

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of

the Paperwork Reduction Act of 1995, for opportunity for public comment

on proposed data collection projects, the National Heart, Lung, and

Blood Institute (NHLBI), the National Institutes of Health (NIH), will

publish periodic summaries of proposed projects to be submitted to the

Office of Management and Budget (OMB) for review and approval. This

proposed information collection was previously published in Volume 62,

Number 86 of the Federal Register on May 5, 1997 (page 24,492) and

allowed 60 days for public comment. One comment was received. An

individual requested a summary of the study protocol, which was

provided to them. The National Institutes of Health may not conduct or

sponsor, and the respondent is not required to respond to, an

information collection that has been extended, revised or implemented

on or after October 1, 1995 unless it displays a currently valid OMB

control number.

Proposed Collection

Title: National Donor Research and Education Study-II. Type of

Information Collection Request: Reinstatement with changes to OMB

#0925-0383, Expiration date: 1/31/96. Need and Use of Information

Collection: This study is the second large anonymous mail survey to be

sent to a random sample of blood donors at five blood centers

participating in the Retrovirus Epidemiology Donor Study (REDS). In

addition to the REDS blood centers, this survey will also be sent to a

sample of donors in selected non-REDS regions that utilize a variety of

donor incentives. Study results will provide data for monitoring the

safety of the U.S. blood supply, and will facilitate the development,

evaluation and refinement of educational, recruitment and qualification

strategies for U.S. blood donors. The proposed new study will update

and extend the unique findings obtained in the first blood donor survey

so as to minimize the likelihood that donors with risk factors for

transfusion-transmitted diseases will enter the blood donor pool. There

is a strong likelihood that, like the first survey effort, the

resulting findings will be directly applied to blood banking

operational practice. The new survey is specifically designed to obtain

data on the prevalence and impact of donor incentives on donor

retention and blood safety. The FDA has identified this as a priority

area for investigation. Other specific objectives of this survey are

to: (1) Evaluate donor understanding and acceptance, and the safety

impact of newly-changed laboratory and donor screening procedures that

have been implemented since the previous donor survey study (e.g.,

removal of the confidential unit exclusion ``CUE'' process at two REDS

sites; additional questions about Creutzfeldt-jakob and parasitic

diseases; and addition of HIV p24 antigen testing); (2) Estimate the

efficacy, safety impact and donor acceptance of new donor screening

procedures that are anticipated to occur within the next 12-24 months

(e.g., improved CUE procedures, implementation of computer-assisted

donor screening); (3) Provide ``pre-'' (baseline) and ``post-''

(evaluation) measures for new donor qualification procedures expected

to occur operationally at blood centers within the time period of study

including: deferral for intranasal cocaine use in the past year;

modification of the time period for sexual risk deferrals from ``since

1977'' to within the past (12 or 24) months; clarification of wording

regarding sexual contact with ``at-risk'' individuals; and addition of

questions about donating primarily for the purpose of receiving the

test results for the AIDS virus; (4) Assess changes in the prevalence

and characteristics of donors who report donating for therapeutic

reasons (e.g., those with iron storage disease), and donors who report

donating primarily to receive test results for the AIDS virus as a

result of the March 1996 implementation of HIV p24 antigen testing; (5)

Determine the extent to which active donors with reactive tests for

anti-HBc and syphilis have increased levels of behavioral risks that

should have resulted in deferral; (6) Measure the extent to which

seropositivity for current syphilis screening tests predicts a recent

history of diagnosed syphilis; (7) Measure blood donor knowledge of

infectious disease risks and the behavioral factors that should defer

them from donating, to identify weaknesses in the current donor

educational process, and (8) Assess the attitudes of donors regarding

establishment of stored frozen repositories from their donations, use

of these samples for future research testing designed to improve

transfusion safety, and the adequacy of different levels of

[[Page 67644]]

informed consent. Frequency of Response: One-time data collection.

Affected Public: Individuals.

----------------------------------------------------------------------------------------------------------------

Estimated

Estimated Average total

Estimated number of burden annual

Type of respondents number of responses hours per burden

respondents per responses hours

respondent requested

----------------------------------------------------------------------------------------------------------------

Blood Donors................................................ 78,000 1 .3333 25,997

----------------------------------------------------------------------------------------------------------------

The annualized cost to respondents is estimated at: $259,974 (based

on $10 per hour). There are no Capital Costs to report. There are no

Operating or Maintenance Costs to report.

Request For Comments

Written comments and/or suggestions from the public and affected

agencies are invited on one or more of the following points: (1)

Whether the proposed collection of information is necessary for the

proper performance of the function of the agency, including whether the

information will have practical utility; (2) The accuracy of the

agency's estimate of the burden of the proposed collection of

information, including the validity of the methodology and assumptions

used; (3) Ways to enhance the quality, utility, and clarity of the

information to be collected; and (4) Ways to minimize the burden of the

collection of information on those who are to respond, including the

use of appropriate automated, electronic, mechanical or other

technological collection techniques or other forms of information

technology.

Direct Comments To OMB

Written comments and/or suggestions regarding the item(s) contained

in this notice, especially regarding the estimated public burden and

associated response time, should be directed to the: Office of

Management and Budget, Office of Regulatory Affairs, New Executive

Office Building, Room 10235, Washington, DC 20503, Attention: Desk

Officer for NIH. To request more information on the proposed project or

obtain a copy of the data collection plans and instruments contact: Dr.

George J. Nemo, Group Leader, Transfusion Medicine, Scientific Research

Group, Division of Blood Diseases and Resources, NHLBI, NIH, Two

Rockledge Centre, Suite 10042, 6701 Rockledge Drive, MSC 7950,

Bethesda, MD 20892-7950, or call non-toll free number (301) 435-0075 or

e-mail your request, including your address to:

[email protected].

Comments Due Date

Comments regarding this information collection are best assured of

having their full effect if received on or before January 28, 1998.

Dated: December 17, 1997.

Sheila E. Merritt,

Executive Officer, NHLBI.

[FR Doc. 97-33745 Filed 12-24-97; 8:45 am]

BILLING CODE 4140-01-M

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.